DexCom develops and markets continuous glucose monitoring (CGM) systems, a type of device that continuously tracks blood sugar levels. The technology isn't exactly new anymore, and it has enjoyed ...
DexCom reported revenue of $1.21 billion in the third quarter, up 22% year over year, with U.S. revenue growing by 21% and international revenue growing by 22%. Adjusted net income was $0.61 per share ...
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...
During glucose-monitoring specialist Dexcom's Investor Day on Thursday, CEO Jake Leach announced the release of its Dexcom G8 continuous glucose monitor, which Leach describes as a "completely new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results